TYME - Tyme shares soar on metabolomic technology platform patent win

Tyme Technologies (TYME) shares surge more than 38% premarket after being granted additional patent claims related to the company’s metabolomic technology platform.The company received notification that the United States Patent and Trademark Office granting it the additional patent claims.The patent, U.S. Patent No. 11,058,638, involves a targeted delivery of therapeutics to cancer cells."This technology could provide Tyme an opportunity to expand its current cancer-metabolism based approach with a drug delivery platform that’s aimed to deliver toxic therapies in a targeted manner that could offer improved safety and efficacy for a range of anticancer drugs," Chief Scientific Officer Steve Hoffman said.The company also said that it plans to initiate further studies on the delivery technology this year.

For further details see:

Tyme shares soar on metabolomic technology platform patent win